Form 8-K - Current report:
SEC Accession No. 0001213900-24-101663
Filing Date
2024-11-22
Accepted
2024-11-22 16:58:15
Documents
17
Period of Report
2024-11-20
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0222330-8k_elevai.htm   iXBRL 8-K 33195
2 CERTIFICATE OF AMENDMENT FILED ON NOVEMBER 20, 2024 ea022233001ex3-1_elevai.htm EX-3.1 1335
3 PRESS RELEASE DATED AS OF NOVEMBER 22, 2024 ea022233001ex99-1_elevai.htm EX-99.1 6674
4 GRAPHIC ex3-1_001.jpg GRAPHIC 899403
5 GRAPHIC ex3-1_002.jpg GRAPHIC 94533
  Complete submission text file 0001213900-24-101663.txt   1592326

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE elab-20241120.xsd EX-101.SCH 3033
7 XBRL LABEL FILE elab-20241120_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE elab-20241120_pre.xml EX-101.PRE 22371
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0222330-8k_elevai_htm.xml XML 3912
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

EIN.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41875 | Film No.: 241490686
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)